Table 1.
Clinicopathological characteristics of 165 patients treated with neoadjuvant chemotherapy (NCT)
| Factors | No. (%) | ||
|---|---|---|---|
| Total | pCR | non-pCR | |
| age (years) | |||
| ≤ 45 | 63 (38.18) | 19 (42.22) | 44 (36.67) |
| > 45 | 102 (61.82) | 26 (57.78) | 76 (63.33) |
| BMI (kg/m2) | |||
| < 25 | 121 (73.33) | 35 (77.78) | 86 (71.67) |
| ≥ 25 | 44 (26.67) | 10 (22.22) | 34 (28.33) |
| Menopausal status | |||
| Postmenopausal | 77 (46.67) | 22 (48.89) | 55 (45.83) |
| Premenopausal | 88 (53.33) | 23 (51.11) | 65 (54.17) |
| Multifocality | |||
| Multifocal | 37 (22.42) | 9 (20.00) | 28 (23.33) |
| Unifocal | 128 (77.58) | 36 (80.00) | 92 (76.67) |
| Local invasion | |||
| Yes | 7 (4.24) | 1 (2.22) | 6 (5.00) |
| No | 158 (95.76) | 44 (97.78) | 114 (95.00) |
| LVI | |||
| Absent | 124 (75.15) | 40 (88.89) | 84 (70.00) |
| Present | 41 (24.85) | 5 (11.11) | 36 (30.00) |
| Clinical tumor size | |||
| T1 | 19 (11.52) | 6 (13.33) | 13 (10.83) |
| T2 | 123 (74.55) | 32 (71.11) | 91 (75.83) |
| T3 | 23 (13.94) | 7 (15.56) | 16 (13.33) |
| Lymph node status | |||
| N0 | 52 (31.52) | 13 (28.89) | 39 (32.50) |
| N1–2 | 113 (68.48) | 32 (71.11) | 81 (67.50) |
| Histological grade | |||
| I-II | 53 (32.12) | 12 (26.67) | 41 (34.17) |
| III | 112 (67.88) | 33 (73.33) | 79 (65.83) |
| Histologic type | |||
| IDC | 152 (92.12) | 44 (97.78) | 108 (90.00) |
| Others | 13 (7.88) | 1 (2.22) | 12 (10.00) |
| Estrogen receptor | |||
| Negative | 111 (67.27) | 38 (84.44) | 73 (60.83) |
| Positive | 54 (32.73) | 7 (15.56) | 47 (39.17) |
| Progesterone receptor | |||
| Negative | 83 (50.30) | 29 (64.44) | 54 (45.00) |
| Positive | 82 (49.70) | 16 (35.56) | 66 (55.00) |
| Hormone receptor | |||
| Negative | 82 (49.70) | 28 (62.22) | 54 (45.00) |
| Positive | 83 (50.30) | 17 (37.78) | 66 (55.00) |
| HER2 | |||
| Negative | 84 (50.91) | 18 (40.00) | 66 (55.00) |
| Positive | 81 (49.09) | 27 (60.00) | 54 (45.00) |
| Ki67 | |||
| ≤ 60% | 118 (71.52) | 25 (55.56) | 93 (77.50) |
| > 60% | 47 (28.48) | 20 (44.44) | 27 (22.50) |
| Molecular subtype | |||
| Luminal B | 45 (27.27) | 2 (4.44) | 43 (35.83) |
| HER2 enriched | 69 (41.82) | 27 (60.00) | 42 (35.00) |
| Triple negative | 51 (30.91) | 16 (35.56) | 35 (29.17) |
| NCT regimen | |||
| TEC | 86 (52.12) | 17 (37.78) | 69 (57.50) |
| TCbH | 79 (47.88) | 28 (62.22) | 51 (42.50) |
| NCT time, cycles | |||
| ≤ 4 | 28 (16.97) | 4 (8.89) | 24 (20.00) |
| > 4 | 137 (83.03) | 41 (91.11) | 96 (80.00) |
| Hemoglobin(g/L) | |||
| ≤ 120 | 42 (25.45) | 6 (13.33) | 36 (30.00) |
| > 120 | 123 (74.55) | 39 (86.67) | 84 (70.00) |
Abbreviations: NCT Neoadjuvant chemotherapy, BMI body mass index, IDC Invasive ductal carcinoma, HER2 Human epidermal growth factor receptor 2, LVI lymphovascular invasion, Others: invasive lobular carcinoma, metaplastic carcinoma and medullary carcinoma, pCR pathologic complete response